U.S. pharma giant copyright scrapped two experimental weight loss products final calendar year—a once-daily tablet, lotiglipron, because of elevated liver enzymes and a 2 times-each day pill, danuglipron, on account of strong side effects—but CEO Albert Bourla has claimed the company is set to “Participate in and get” while in the being ove